TransMedics Group, Inc. (TMDX)
| Market Cap | 689.47M |
| Revenue (ttm) | 25.64M |
| Net Income (ttm) | -28.75M |
| Shares Out | 27.62M |
| EPS (ttm) | -1.06 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 6 |
| Last Price | $22.75 |
| Previous Close | $24.96 |
| Change ($) | -2.21 |
| Change (%) | -8.85% |
| Day's Open | 23.87 |
| Day's Range | 22.42 - 24.21 |
| Day's Volume | 718,202 |
| 52-Week Range | 11.51 - 49.50 |
TransMedics (TMDX) delivered earnings and revenue surprises of -3.57% and 1.78%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Shares of TransMedics Group (NASDAQ:TMDX) were flat in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share were up 30.95% over the past year to ($0.29), whic...
ANDOVER, Mass., May 4, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage...
TransMedics is looking to disrupt an entire industry and help thousands of transplant patients in the U.S. in the process.
ANDOVER, Mass., April 20, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-st...
The FDA Advisory Committee has voted in favor of TransMedics Group Inc (NASDAQ: TMDX) after reviewing clinical evidence from the OCS Heart EXPAND trial, the associated Continued Access Protocol (CAP) re...
ANDOVER, Mass., April 6, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-sta...
Jonah Lupton of Lupton Capital was focused on TransMedics Group Inc (NASDAQ: TMDX) Tuesday. The Nasdaq halted trading in TransMedics stock while the FDA reviews the company's OCS Heart System.
ANDOVER, Mass., April 6, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-sta...
ANDOVER, Mass., March 24, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-st...
And it probably won't take them long to do it.
TransMedics (TMDX) delivered earnings and revenue surprises of 8.00% and 24.62%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of TransMedics Group (NASDAQ:TMDX) moved higher in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share were up 46.51% over the past year to ($0.23), w...
ANDOVER, Mass., March 2, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-sta...
ANDOVER, Mass., March 1, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-sta...
ANDOVER, Mass., Feb. 16, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-sta...
ANDOVER, Mass., Feb. 16, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-sta...
Abrams Capital Management leader David Abrams (Trades, Portfolio) revealed earlier this week he reduced his stake in TransMedics Group Inc. (NASDAQ:TMDX) by 25.01%.
Corcept Therapeutics (NASDAQ: CORT) shares were trading lower Tuesday after the company reported preliminary fourth-quarter sales results and issued fiscal year 2021 sales guidance. Corcept Therapeutics...
TransMedics saw steady growth in 2019 after the public offering. Its transformative approach to organ transplantation has real benefits and seems to have traction as well, with Covid-19 only showing ado...
ANDOVER, Mass., Dec. 24, 2020 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-sta...
ANDOVER, Mass., Dec. 23, 2020 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-sta...
LONDON--(BUSINESS WIRE)--Deep Pharma Intelligence names Nanox Imaging (NASDAQ:NNOX), TransMedics, Inc. (NASDAQ: TMDX), Outset Medical, Inc. (NASDAQ:OM), Eargo, Inc. (NASDAQ:EAR), and Silk Road Medical, ...
Three currently-undervalued MedTech stocks are flourishing on the back of a few uptrends.
TransMedics Group's (TMDX) CEO Waleed Hassanein on Q3 2020 Results - Earnings Call Transcript
TransMedics (TMDX) delivered earnings and revenue surprises of 42.42% and 19.58%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
ANDOVER, Mass., Nov. 4, 2020 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stag...
ANDOVER, Mass., Oct. 29, 2020 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-sta...
TransMedics (TMDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ANDOVER, Mass., Oct. 21, 2020 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-sta...
ANDOVER, Mass., Sept. 28, 2020 (GLOBE NEWSWIRE) -- TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with ...
ANDOVER, Mass., Sept. 01, 2020 (GLOBE NEWSWIRE) -- TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with ...
TransMedics Group, Inc. (TMDX) CEO Waleed Hassanein on Q2 2020 Results - Earnings Call Transcript
ANDOVER, Mass., Aug. 05, 2020 (GLOBE NEWSWIRE) -- TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with e...
Here we discuss three medical product stocks that are due to report soon and are likely to beat estimates on earnings, riding on a host of factors.
TransMedics (TMDX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ANDOVER, Mass., July 28, 2020 (GLOBE NEWSWIRE) -- TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with e...
ANDOVER, Mass., July 23, 2020 (GLOBE NEWSWIRE) -- TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with e...
TransMedics: A Medical Device Company Creating A Healthy Ecosystem
Shares slumped after the company announced it's raising capital.
ANDOVER, Mass., May 26, 2020 (GLOBE NEWSWIRE) -- TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with en...
ANDOVER, Mass., May 26, 2020 (GLOBE NEWSWIRE) -- TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with en...
Primary Effectiveness and Safety Endpoints Were Met. The OCS Liver Achieved Statistical Superiority of The Primary Effectiveness Endpoint by Demonstrating Significant Reduction of Early Allograft Dysfun...
TransMedics Group's (TMDX) CEO Waleed Hassanein on Q1 2020 Results - Earnings Call Transcript
TransMedics Expects Strong 2020 Growth Trajectory
ANDOVER, Mass., March 17, 2020 (GLOBE NEWSWIRE) -- TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with ...
TransMedics Group, Inc. (TMDX) CEO Waleed Hassanein on Q4 2019 Results - Earnings Call Transcript
Disrupting Organ Transplants: TransMedics And In-Kind Competitors
TransMedics (TMDX) successfully completes heart transplants from DCD donors, using its OCS technology.
The current transportation process is riddled with inefficiencies and waste. TransMedics is on a mission to fix the problem and deliver huge returns for investors.
About TMDX
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG, a portable perfusion, ventilation, and monitoring system tha... [Read more...]
| Industry Medical Devices | IPO Date May 2, 2019 |
| Stock Exchange NASDAQ | Ticker Symbol TMDX |
Financial Performance
In 2020, TMDX's revenue was $25.64 million, an increase of 8.62% compared to the previous year's $23.60 million. Losses were -$28.75 million, -14.31% less than in 2019.
Analyst Forecasts
According to 5 analysts, the average rating for TMDX stock is "Buy." The 12-month stock price forecast is 53.00, which is an increase of 132.97% from the latest price.